Governments, donors should follow PMI model of testing drugs for quality

Published on December 11, 2012 at 3:52 AM · No Comments

"[W]e are losing the global fight against bad medicines," and though "[s]ome progress is being made," the "problem is that ... crackdowns tend to focus on counterfeit drugs" while a "much bigger public health problem ... is substandard drugs that are the result of shoddy manufacturing and handling -- or perhaps worse, deliberate corner-cutting," Roger Bate, a resident scholar at the American Enterprise Institute, writes in an opinion piece in The Hill's "Congress Blog." He continues, "In poor countries, a frightfully high number of bad drugs reach patients through legitimate supply chains and even donor programs underwritten by U.S. and European taxpayers," increasing the risk of harm to patients and the development of drug-resistant disease strains.

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post